TCBPW Net Income From Continuing Ops from 2010 to 2024

TCBPW Stock  USD 0.02  0  24.67%   
TC BioPharm Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss will likely drop to about -6.2 M in 2024. During the period from 2010 to 2024, TC BioPharm Net Loss regression line of quarterly data had r-squared of  0 and coefficient of variation of (38.07). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-5.9 M
Current Value
-6.2 M
Quarterly Volatility
2.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check TC BioPharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TC BioPharm's main balance sheet or income statement drivers, such as Interest Income of 1.9 K, Depreciation And Amortization of 638 K or Interest Expense of 78.9 K, as well as many indicators such as Price To Sales Ratio of 0.62, Dividend Yield of 0.0 or PTB Ratio of 0.3. TCBPW financial statements analysis is a perfect complement when working with TC BioPharm Valuation or Volatility modules.
  
Check out the analysis of TC BioPharm Correlation against competitors.

Latest TC BioPharm's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of TC BioPharm plc over the last few years. It is TC BioPharm's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TC BioPharm's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Very volatile
   Net Income From Continuing Ops   
       Timeline  

TCBPW Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(6,214,176)
Coefficient Of Variation(38.07)
Mean Deviation981,567
Median(6,067,984)
Standard Deviation2,365,693
Sample Variance5.6T
Range12.2M
R-Value(0.03)
Mean Square Error6T
R-Squared0
Significance0.91
Slope(17,086)
Total Sum of Squares78.4T

TCBPW Net Income From Continuing Ops History

2024-6.2 M
2023-5.9 M
2022-1.4 M
2021-13.6 M
2020-5.5 M

About TC BioPharm Financial Statements

TC BioPharm investors use historical fundamental indicators, such as TC BioPharm's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TC BioPharm. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-5.9 M-6.2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for TCBPW Stock Analysis

When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.